EGFR and ovarian carcinoma: Targeted studies on ZEB1 have shown that FOXM1 and EGFR/ERBB2 can upregulate ZEB1, promoting ovarian cancer peritoneal metastasis, while combined treatment with lapatinib (a dual kinase inhibitor of EGFR/ERBB1 and ERBB2) and thiostrepton (an inhibitor of FOXM1) can reverse this mechanism and inhibit ovarian cancer peritoneal metastasis 51.